vocabulary: "1.0.0" info: provider: Axsome Therapeutics description: >- Domain vocabulary for Axsome Therapeutics, a biopharmaceutical company focused on the central nervous system (CNS). This vocabulary catalogs marketed products, pipeline candidates, therapeutic areas, mechanisms of action, and corporate / regulatory touchpoints. Axsome does not currently expose a public developer API surface, so the vocabulary is organized around the company's clinical, commercial, and disclosure footprint rather than around HTTP resources. created: "2026-05-23" modified: "2026-05-23" organizationalProfile: legalName: Axsome Therapeutics, Inc. ticker: AXSM exchange: NASDAQ industry: Biopharmaceuticals therapeuticFocus: Central Nervous System (CNS) headquarters: street: One World Trade Center city: New York state: NY postalCode: "10007" country: USA website: https://www.axsome.com/ contact: https://www.axsome.com/contact-us/ products: - name: Auvelity genericName: Dextromethorphan and Bupropion indication: Major Depressive Disorder (MDD) in adults therapeuticArea: Depression mechanism: - NMDA receptor antagonist - Sigma-1 receptor agonist - CYP2D6 inhibitor regulatoryStatus: FDA Approved productSite: https://www.auvelity.com hcpSite: https://www.auvelityhcp.com - name: Sunosi genericName: Solriamfetol indication: Excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) in adults therapeuticArea: Sleep-Wake Disorders mechanism: - Dopamine-norepinephrine reuptake inhibitor (DNRI) regulatoryStatus: FDA Approved; EMA Authorized; Health Canada Approved productSite: https://www.sunosi.com hcpSite: https://www.sunosihcp.com - name: Symbravo genericName: Meloxicam and Rizatriptan indication: Acute treatment of migraine with or without aura in adults therapeuticArea: Migraine mechanism: - NSAID (COX-2 selective; meloxicam) - 5-HT1B/1D receptor agonist (rizatriptan) regulatoryStatus: FDA Approved productSite: https://www.symbravo.com hcpSite: https://www.symbravohcp.com pipeline: - code: AXS-05 components: Dextromethorphan and Bupropion indications: - Agitation associated with dementia due to Alzheimer's disease - Smoking cessation mechanism: - NMDA receptor antagonist - Sigma-1 receptor agonist - DNRI / CYP2D6 inhibitor status: Approved for Alzheimer's disease agitation; in development for additional indications - code: AXS-12 genericName: Reboxetine indications: - Narcolepsy mechanism: - Selective norepinephrine reuptake inhibitor (NRI) designations: - FDA Orphan Drug Designation (narcolepsy) status: Investigational - code: AXS-14 genericName: Esreboxetine indications: - Fibromyalgia mechanism: - Selective norepinephrine reuptake inhibitor (NRI), single enantiomer status: Investigational therapeuticAreas: - name: Depression products: [Auvelity] pipeline: [] - name: Migraine products: [Symbravo] pipeline: [] - name: Alzheimer's Disease Agitation products: [] pipeline: [AXS-05] - name: Excessive Daytime Sleepiness products: [Sunosi] pipeline: [] - name: Narcolepsy products: [Sunosi] pipeline: [AXS-12] - name: Fibromyalgia products: [] pipeline: [AXS-14] - name: Smoking Cessation products: [] pipeline: [AXS-05] mechanismsOfAction: - id: nmda-antagonist label: NMDA Receptor Antagonist description: Antagonism of the N-methyl-D-aspartate glutamate receptor; implicated in rapid-acting antidepressant and neuroprotective effects. - id: sigma1-agonist label: Sigma-1 Receptor Agonist description: Activation of sigma-1 chaperone receptor, modulating neuroplasticity and intracellular signaling. - id: dnri label: Dopamine-Norepinephrine Reuptake Inhibitor (DNRI) description: Inhibition of dopamine and norepinephrine transporters, promoting wakefulness and mood effects. - id: nri label: Norepinephrine Reuptake Inhibitor (NRI) description: Selective inhibition of the norepinephrine transporter. - id: cyp2d6-inhibitor label: CYP2D6 Inhibitor description: Inhibits hepatic CYP2D6 metabolism to extend exposure of a co-administered substrate. - id: cox-nsaid label: NSAID (COX-2 Selective) description: Non-steroidal anti-inflammatory drug with COX-2 selective inhibition. - id: 5ht1b-1d-agonist label: 5-HT1B/1D Receptor Agonist description: Triptan-class serotonergic agonist used in acute migraine therapy. - id: taar1-agonist label: Trace Amine-Associated Receptor 1 (TAAR1) Agonist description: Modulation of TAAR1 implicated in monoaminergic neurotransmission. regulatoryFootprint: - authority: U.S. Food and Drug Administration (FDA) interactions: - Auvelity NDA approval - Sunosi NDA approval - Symbravo NDA approval (January 2025) - AXS-05 sNDA approval for Alzheimer's disease agitation - AXS-12 Orphan Drug Designation (narcolepsy) - authority: European Medicines Agency (EMA) interactions: - Sunosi (solriamfetol) marketing authorization with SmPC and PIL - authority: Health Canada interactions: - Sunosi product monograph (English and French) - authority: U.S. Securities and Exchange Commission (SEC) interactions: - 10-K, 10-Q, 8-K filings under CIK 0001579428 - NASDAQ listing as AXSM investorAndDisclosureSurface: - kind: PressReleases url: https://www.axsome.com/news-events/ - kind: RSS url: https://www.axsome.com/feed/ - kind: SECFilings url: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001579428&type=10-K - kind: Webcasts url: https://www.axsome.com/webcasts-presentations/ - kind: AnalystCoverage url: https://www.axsome.com/analyst-coverage/ - kind: ShareholderServices url: https://www.axsome.com/shareholder-services/ publicDeveloperSurface: status: none notes: >- Axsome Therapeutics does not publish a developer portal, public OpenAPI specification, SDKs, CLI, webhooks API, or partner API at this time. The corporate site is a WordPress-backed marketing presence with a standard RSS feed; HCP and patient microsites for Auvelity, Sunosi, and Symbravo publish prescribing and educational content but not programmatic interfaces. Programmatic access to Axsome data is therefore limited to third-party regulatory data sources (FDA Drugs@FDA, EMA, Health Canada, EDGAR, NASDAQ market data, ClinicalTrials.gov).